HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review

C. T. Lambert, P. B. Sandesara, B. Hirsh, L. J. Shaw, W. Lewis, A. A. Quyyumi, R. F. Schinazi, W. S. Post, L. Sperling

Research output: Contribution to journalReview articlepeer-review

Abstract

The advent of potent highly active antiretroviral therapy (HAART) for persons infected with HIV-1 has led to a “new” chronic disease with complications including cardiovascular disease (CVD). CVD is a significant cause of morbidity and mortality in persons with HIV infection. In addition to traditional risk factors such as smoking, hypertension, insulin resistance and dyslipidaemia, infection with HIV is an independent risk factor for CVD. This review summarizes: (1) the vascular and nonvascular cardiac manifestations of HIV infection; (2) cardiometabolic effects of HAART; (3) atherosclerotic cardiovascular disease (ASCVD) risk assessment, prevention and treatment in persons with HIV-1 infection.

Original languageEnglish (US)
Pages (from-to)411-424
Number of pages14
JournalHIV Medicine
Volume17
Issue number6
DOIs
StatePublished - Jun 1 2016

Keywords

  • HIV
  • atherosclerotic cardiovascular disease
  • cardiovascular disease
  • endothelial dysfunction
  • highly active antiretroviral therapy
  • prevention

ASJC Scopus subject areas

  • Health Policy
  • Infectious Diseases
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'HIV, highly active antiretroviral therapy and the heart: a cellular to epidemiological review'. Together they form a unique fingerprint.

Cite this